ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01904409
Recruitment Status : Completed
First Posted : July 22, 2013
Last Update Posted : April 10, 2018
Sponsor:
Information provided by (Responsible Party):
Valeant Pharmaceuticals International, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : June 2015
  Actual Study Completion Date : July 2015
  Certification/Extension First Submitted : December 13, 2017